ZyVersa Therapeutics, Inc.
ZVSA
$0.7899
-$0.0111-1.39%
09/30/2024 | 06/30/2024 | ||||
---|---|---|---|---|---|
Revenue | -- | -- | |||
Total Other Revenue | -- | -- | |||
Total Revenue | -- | -- | |||
Cost of Revenue | -- | -- | |||
Gross Profit | -- | -- | |||
SG&A Expenses | -10.33% | -11.62% | |||
Depreciation & Amortization | -- | -- | |||
Other Operating Expenses | -- | -- | |||
Total Operating Expenses | -17.59% | -2.57% | |||
Operating Income | 17.59% | 2.57% | |||
Income Before Tax | 12.81% | 2.57% | |||
Income Tax Expenses | -- | -- | |||
Earnings from Continuing Operations | 13.11% | 2.23% | |||
Earnings from Discontinued Operations | -- | -- | |||
Extraordinary Item & Accounting Change | -- | -- | |||
Minority Interest in Earnings | -- | -- | |||
Net Income | 13.11% | 2.23% | |||
EBIT | 17.59% | 2.57% | |||
EBITDA | 17.57% | 2.57% | |||
EPS Basic | 26.61% | 26.97% | |||
Normalized Basic EPS | 26.35% | 27.23% | |||
EPS Diluted | 26.61% | 26.97% | |||
Normalized Diluted EPS | 26.35% | 27.23% | |||
Average Basic Shares Outstanding | 18.39% | 33.88% | |||
Average Diluted Shares Outstanding | 18.39% | 33.88% | |||
Dividend Per Share | -- | -- | |||
Payout Ratio | -- | -- |